Asset Publisher

Draft Provider-Administered Oncology Drug Policies

Draft policies are listed below. If there are no policies listed, it means there are currently no policies in draft status.

Comment on Draft Drug Policies

Participating providers are invited to submit for consideration scientific, evidence-based information, professional consensus opinions, and other information supported by medical literature relevant to our draft policies.

We accept comments for 45 days from the posting date listed on the draft policy. 

Make sure your voice is heard by providing feedback directly to us:

  • Send comments and supporting documentation to us by mail or fax:

Blue Cross and Blue Shield of Alabama
Attn: Pharmacy Department
P.O. Box 995
Birmingham, AL 35298-0001

Fax: 205-220-9576

Draft Policies

Policy # Policy Title Print View
-90682 Tecvayli™ (teclistamab-cqyv)
VP-90008 Aloxi® (palonosetron)
VP-90074 Cabazitaxel: Jevtana®; Cabazitaxel§
VP-90100 Provenge® (sipuleucel-T)
VP-90157 Kyprolis® (carfilzomib)
VP-90266 Darzalex™ (daratumumab)
VP-90267 Portrazza™ (necitumumab)
VP-90274 Imlygic® (talimogene laherparepvec)
VP-90283 Sustol® (granisetron extended-release)
VP-90317 Besponsa® (inotuzumab ozogamicin)
VP-90336 Cinvanti® (aprepitant)
VP-90363 Akynzeo® (fosnetupitant/palonosetron)
VP-9038 Erbitux® (cetuximab)
VP-90426 Elzonris™ (tagraxofusp-erzs)
VP-90503 Reblozyl® (luspatercept-aamt)
VP-90531 Jelmyto® (mitomycin)
VP-90590 Breyanzi® (lisocabtagene maraleucel)
VP-90607 Rybrevant® (amivantamab-vmjw)
VP-90663 Carvykti™ (ciltacabtagene autoleucel)
VP-90679 Pedmark® (sodium thiosulfate)
VP-90691 Adstiladrin® (nadofaragene firadenovec-vncg)
VP-90750 Tevimbra™ (tislelizumab-jsgr)
VP-90753 Anktiva® (nogapendekin alfa inbakicept-pmln)